TOGETHER
WE’RE MORE THAN
HIGHLY EFFECTIVE INSULIN FOR DOGS AND CATS

We're giving pet owners and clinics the education and resources they need to care for diabetic pets

IMPORTANT SAFETY INFORMATION:
PROZINC® (protamine zinc recombinant human insulin) is for use in dogs and cats only. The most common adverse reactions were lethargy, anorexia, hypoglycemia, vomiting, seizures, shaking (dogs only), diarrhea, and ataxia. For more information, see full prescribing information.
Boehringer Ingelheim continuously invests in research and development to deliver science-based and advanced products like PROZINC® (protamine zinc recombinant human insulin), as well as developing programs and resources that can help you educate and support your clients.

**CLINIC RESOURCES**

**Technician Training**
Staff training and support tools are available, including three new, online technician training modules. These courses offer 3 hours of continuing education (CE) each! Visit the Boehringer Ingelheim Learning Center for more information at biahlearningcenter.com.

**Latest Research**
Access the latest research on diabetes management at PROZINC.us, including the most robust field studies for safety and efficacy in dogs and cats.

**CLIENT EDUCATION**

**Educational Brochures**
Help your clients understand what diabetes is, how their dog or cat developed it, and how to treat it with these easy-to-read educational brochures.

**Educational Videos**
A variety of video resources are available on managing canine and feline diabetes.

**YOU CAN DO THIS! Video series found on PROZINC.us.**

**IMPORTANT SAFETY INFORMATION:** PROZINC® (protamine zinc recombinant human insulin) is for use in dogs and cats only. Keep out of the reach of children. Animals presenting with severe ketoacidosis, anorexia, lethargy, and/or vomiting should be stabilized with short-acting insulin and appropriate supportive therapy until their condition is stabilized. As with all insulin products, careful patient monitoring for hypoglycemia and hyperglycemia is essential to attain and maintain adequate glycemic control and to prevent associated complications. Overdose can result in profound hypoglycemia and death. The most common adverse reactions were lethargy, anorexia, hypoglycemia,
We created these resources to help make treating diabetes and tracking their pet’s health more efficient and convenient for your clients.

**Diabetes Care Kits for Pet Owners**

**Administration Booklet**

**Single Insulin Dose Treatment Guide**

**At-Home Care Diary**

**Dosing Magnet**

**Ice Pack**

**Pet Water Bowl**

**Branded Cooler**

**Vial Covers**

**TECHNICAL SUPPORT**

Diabetes is a complex medical condition that can present unique challenges. We’re here to help you solve those challenges. If you have any questions or concerns about diabetes treatment or PROZINC® (protamine zinc recombinant human insulin), call 1-888-637-4251 (OPT. 3) and our team of experienced veterinarians will be happy to help.

Simply contact your Boehringer Ingelheim Sales Representative or Professional Services Veterinarian for these tools and resources that are always available to you.

vomiting, seizures, shaking (dogs only), diarrhea, and ataxia. Many of the adverse reactions, such as lethargy, seizures, shaking (dogs only), and ataxia, are associated with hypoglycemia. Glucocorticoid and progestogen use should be avoided. The safety and effectiveness of PROZINC in puppies, kittens, or breeding, pregnant, and lactating animals has not been evaluated. PROZINC is contraindicated during episodes of hypoglycemia and in animals sensitive to protamine zinc recombinant human insulin or any other ingredients in PROZINC. For more information, please see full prescribing information.
The Only Recombinant Insulin for Dogs and Cats.\textsuperscript{1,2,3,5}

The Convenient Insulin Choice for Veterinarians.

Stock a single insulin that's proven to be highly effective in dogs and cats!

The choice for canines

• Once-daily dosing is a reality for most canines due to extended duration of action.\textsuperscript{1}

• In a study, most dogs showed reduction of clinical signs by Day 14.\textsuperscript{3}

• In the same study, diabetic control was attained at similar rates in both naive and previously insulin-treated populations.\textsuperscript{3}

The choice for felines

• Proven to deliver glycemic control comparable to glargine and no detectable difference in remission rate.\textsuperscript{4}

• In a study, almost HALF of all felines treated showed improvement in clinical signs as soon as 7 days.\textsuperscript{5,6}

• Another study also showed that the rapid glycemic control of PROZINC® (protamine zinc recombinant human insulin) promotes conditions that favor remission.\textsuperscript{6}

IMPORTANT SAFETY INFORMATION:

PROZINC® (protamine zinc recombinant human insulin) is for use in dogs and cats only. The most common adverse reactions were lethargy, anorexia, hypoglycemia, vomiting, seizures, shaking (dogs only), diarrhea, and ataxia. For more information, see full prescribing information.

\textsuperscript{*}PROZINC® (protamine zinc recombinant human insulin) is approved for twice-daily use in cats.\textsuperscript{2}


\textsuperscript{6} Gostelow et al. Systematic review of feline diabetic remission separating fact from opinion. \textit{The Veterinary Journal.} 2014.
ProZinc®
(protagonate zinc recombinant human insulin)

40 IU/mL

Caution: Federal law restricts this drug to use by or on the order of a licensed veterinarian.

Description: ProZinc® is a sterile aqueous protamine zinc suspension of recombinant human insulin. Each mL contains:

- recombinant human insulin 40 International Units (IU)
- protamine sulfate 0.466 mg
- zinc oxide 0.088 mg
- glycerin 16.00 mg
- dibasic sodium phosphate, heptahydrate 3.78 mg
- phenol (added as preservative) 2.50 mg
- hydrochloric acid 1.63 mg
- water for injection (maximum) 1005 mg

pH is adjusted with hydrochloric acid and/or sodium hydroxide.

Indication: ProZinc (protamine zinc recombinant human insulin) is indicated for the reduction of hyperglycemia and hyperglycemia-associated clinical signs in cats with diabetes mellitus.

Dosage and Administration: USE OF A SYRINGE OTHER THAN A U-40 SYRINGE WILL RESULT IN INCORRECT DOSSING. FOR SUBCUTANEOUS INJECTION ONLY.

DO NOT SHAKE OR AGITATE THE VIAL.

ProZinc should be mixed by gently rolling the vial prior to withdrawing each dose from the vial. Once mixed, ProZINC suspension has a white, cloudy appearance. Clumps or visible white particles can form in insulin suspensions; do not use the product if clumps or visible white particles persist after gently rolling the vial.

Using a U-40 insulin syringe, the injection should be administered subcutaneously on the back of the neck or on the side of the cat.

Always provide the Client Information Sheet with each prescription.

The initial recommended PROZINC dose is 0.1 – 0.3 IU insulin/pound of body weight (0.2 – 0.7 IU/kg) every 12 hours. The dose should be given concurrently with or right after a meal. The veterinarian should re-evaluate the cat at appropriate intervals and adjust the dose based on both clinical signs and glucose nadirs until adequate glycemic control has been attained. In an effectiveness field study, glycemic control was considered adequate if the glucose nadir from a 9-hour blood glucose curve was between 80 and 150 mg/dL and clinical signs of hyperglycemia such as polyuria, polydipsia, and weight loss were improved.

Further adjustments in the dosage may be necessary with changes in the cat’s diet, body weight, or concomitant medication, or if the cat develops concurrent infection, inflammation, neoplasia, or an additional endocrine or other medical disorder.

Contraindications: PROZINC is contraindicated in cats sensitive to protamine zinc recombinant human insulin or any other ingredients in PROZINC. PROZINC is contraindicated during episodes of hypoglycemia.

Warnings: User Safety: For use in cats and dogs only. Keep out of the reach of children. Avoid contact with eyes. In case of contact, immediately flush eyes with running water for at least 15 minutes. Accidental injection may cause hypoglycemia. In case of accidental injection, seek medical attention immediately. Exposure to product may induce a local or systemic allergic reaction in sensitized individuals.

Animal Safety: Owners should be advised to observe for signs of hypoglycemia (see Client Information Sheet). Use of this product, even at established doses, has been associated with hypoglycemia. A cat with signs of hypoglycemia should be treated immediately. Glucose should be given orally or intravenously as dictated by clinical signs. Insulin should be temporarily withheld and, if indicated, the dosage adjusted.

Any change in insulin should be made cautiously and only under a veterinarian’s supervision. Changes in insulin strength, manufacturer, type, species (human, animal) or method of manufacture (rDNA versus animal-source insulin) may result in the need for a change in dosage. Appropriate diagnostic tests should be performed to rule out other endocrinopathies in diabetic cats that are difficult to regulate.

Precautions: Cats presenting with severe ketoadidosis, anorexia, lethargy, and/or vomiting should be stabilized with short-acting insulin and appropriate supportive therapy until their condition is stabilized. As with all insulin products, careful patient monitoring for hypoglycemia and hyperglycemia is essential to attain and maintain adequate glycemic control and to prevent associated complications. Overdose can result in profound hypoglycemia and death. Glucocorticoids, progestogens, and certain endocrinopathies can have an antagonistic effect on insulin activity. Glucocorticoid and progestogen use should be avoided.

The safety and effectiveness of PROZINC in breeding, pregnant, and lactating cats has not been evaluated.

Adverse Reactions: Effectiveness Field Study

In a 45-day effectiveness field study, 175 cats received PROZINC. Hypoglycemia (defined as a blood glucose value of < 50 mg/dL) occurred in 71 of the cats at various times throughout the study. Clinical signs of hypoglycemia were generally mild in nature (described as lethargic, sluggish, weak, trembling, uncoordinated, groggy, glassy-eyed or dazed). In 17 cases, the veterinarians provided oral glucose supplementation or food as treatment. Most cases were not associated with clinical signs and received no treatment. One cat had a serious hypoglycemic event associated with stupor, lateral recumbency, hypothermia and seizures.

All cases of hypoglycemia resolved with appropriate therapy and if needed, a dose reduction. Four cats developed diabetic neuropathy during the study as evidenced by plantigrade stance. Three cats entered the study with plantigrade stance, one of which resolved by Day 45. Four cats were diagnosed with diabetic nephropathy, three of which were euthanized due to poor response to treatment. Five other cats were euthanized during the study, one of which had hypoglycemia. Four cats had received PROZINC for less than a week and were euthanized due to worsening concurrent medical conditions.

The following additional clinical observations or diagnoses were reported in cats during the effectiveness field study: vomiting, lethargy, diarrhea, dyspnea, cutaneous or subcutaneous bacterial or fungal infection, dry coat, hair loss, ocular discharge, abnormal vocalization, blood stool, and rapid breathing.

Extended Use Field Study

Cats that completed the effectiveness study were enrolled into an extended use field study. In this study, 145 cats received PROZINC for up to an additional 136 days. Adverse reactions were similar to those reported during the 45-day effectiveness study and are listed in order of decreasing frequency: vomiting, hypoglycemia, anorexia/poor appetite, diarrhea, lethargy, cystitis/menuria, and weakness. Twenty cats had signs consistent with hypoglycemia described as: sluggish, lethargic, unsteady wobbly, seizures, trembling, or dazed. Most of these were treated by the owner or veterinarian with oral glucose supplementation or food; others received intravenous glucose. One cat had a serious hypoglycemic event associated with seizures and blindness. The cat fully recovered after supportive therapy and finished the study. All cases of hypoglycemia resolved with appropriate therapy and if needed, a dose reduction. Fourteen cats died or were euthanized during the extended use study. In two cases, continued use of insulin despite anorexia and signs of hypoglycemia contributed to the deaths. In one case, the owner decided not to continue therapy after a presumed episode of hypoglycemia. The rest were due to concurrent medical conditions or worsening of the diabetes mellitus.

For reported adverse drug events, for technical assistance or to obtain a copy of the Safety Data Sheet (SDS), contact Boehringer Ingelheim at 1-888-537-4255 or online at http://www.fda.gov/reportanimalae.

Information for Cat Owners: Please refer to the Client Information Sheet for Cats for more information about PROZINC. PROZINC, like other insulin products, is not free from adverse reactions. Owners should be advised of the potential for adverse reactions and be informed of the associated clinical signs. Potential adverse reactions include: hypoglycemia, insulin antagonism/resistance, rapid insulin metabolism, insulin-induced hyperglycemia (Somogyi Effect), and local or systemic reactions. The most common adverse reaction observed is hypoglycemia. Signs may include: weakness, depression, behavioral changes, muscle twitching, and anxiety. In severe cases of hypoglycemia, seizures and coma can occur. Hypoglycemia can be fatal if an affected cat does not receive prompt treatment. Appropriate veterinary monitoring of blood glucose, adjustment of insulin dose and regimen as needed, and stabilization of diet and activity help minimize the risk of hypoglycemic episodes. The attending veterinarian should evaluate other adverse reactions on a case-by-case basis to determine if an adjustment in therapy is appropriate, or if alternative therapy should be considered.

Effectiveness: A total of 187 client-owned cats were enrolled in a 45-day field study, with 176 receiving PROZINC. One hundred and fifty-one of these cats were included in the effectiveness analysis. The patients included various purebreds and mixed-breed cats ranging in age from 3 to 19 years and in weight from 4.6 to 20.8 pounds. Of the cats included in the effectiveness analysis, 101 were castrated males, 49 were spayed females, and 1 was an intact female. Cats were started on PROZINC at a dose of 0.1-0.3 IU/lb (0.2-0.7 IU/kg) twice daily. Cats were evaluated at 7, 14, 30, and 45 days after initiation of therapy and the dose was adjusted based on clinical signs and results of 9-hour blood glucose curves on Days 7, 14, and 30.

Effectiveness was based on successful control of diabetes which was defined as improvement in a series of decreasing frequency: vomiting, hypoglycemia, anorexia/poor appetite, diarrhea, lethargy, cystitis/menuria, and weakness. Twenty cats had signs consistent with hypoglycemia described as: sluggish, lethargic, unsteady wobbly, seizures, trembling, or dazed. Most of these were treated by the owner or veterinarian with oral glucose supplementation or food; others received intravenous glucose. One cat had a serious hypoglycemic event associated with seizures and blindness. The cat fully recovered after supportive therapy and finished the study. All cases of hypoglycemia resolved with appropriate therapy and if needed, a dose reduction. Fourteen cats died or were euthanized during the extended use study. In two cases, continued use of insulin despite anorexia and signs of hypoglycemia contributed to the deaths. In one case, the owner decided not to continue therapy after a presumed episode of hypoglycemia. The rest were due to concurrent medical conditions or worsening of the diabetes mellitus.

For additional information about adverse drug experience reporting for animal drugs, contact FDA at 1-888-FDA-VETS or online at http://www.fda.gov/reportanimalae.

Federal law restricts this drug to use by or on the order of a licensed veterinarian.

PROZINC® is a registered trademark of Boehringer Ingelheim Animal Health USA Inc. © 2019 Boehringer Ingelheim Animal Health USA Inc. All rights reserved. US-PET-0697-2021 Revised 08/2019

449986-01